DE68929115D1 - Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe - Google Patents

Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe

Info

Publication number
DE68929115D1
DE68929115D1 DE68929115T DE68929115T DE68929115D1 DE 68929115 D1 DE68929115 D1 DE 68929115D1 DE 68929115 T DE68929115 T DE 68929115T DE 68929115 T DE68929115 T DE 68929115T DE 68929115 D1 DE68929115 D1 DE 68929115D1
Authority
DE
Germany
Prior art keywords
yeast
serum albumin
human serum
production
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68929115T
Other languages
English (en)
Other versions
DE68929115T2 (de
Inventor
Rheinhard Fleer
Hiroshi Fukuhara
Patrice Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8810615A external-priority patent/FR2635115B1/fr
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of DE68929115D1 publication Critical patent/DE68929115D1/de
Publication of DE68929115T2 publication Critical patent/DE68929115T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE68929115T 1988-08-05 1989-08-04 Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe Expired - Lifetime DE68929115T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8810615A FR2635115B1 (fr) 1988-08-05 1988-08-05 Procede de preparation de la serum albumine humaine a partir d'une levure
FR898908897A FR2649991B2 (fr) 1988-08-05 1989-07-03 Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces

Publications (2)

Publication Number Publication Date
DE68929115D1 true DE68929115D1 (de) 2000-01-20
DE68929115T2 DE68929115T2 (de) 2000-06-15

Family

ID=26226839

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68929115T Expired - Lifetime DE68929115T2 (de) 1988-08-05 1989-08-04 Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe

Country Status (13)

Country Link
EP (1) EP0361991B1 (de)
JP (1) JP3068139B2 (de)
KR (1) KR910004800A (de)
AT (1) ATE187775T1 (de)
AU (1) AU623425B2 (de)
DE (1) DE68929115T2 (de)
DK (1) DK175846B1 (de)
FI (1) FI893702A7 (de)
FR (1) FR2649991B2 (de)
HU (1) HUT51329A (de)
NO (1) NO893149L (de)
NZ (1) NZ230229A (de)
PT (1) PT91381B (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017176A1 (en) * 1989-05-22 1990-11-22 Yoshitomi Pharmaceutical Industries Ltd. Albumin gene-containing plasmid, transformant carrying same, production of such transformant and production of albumin
FR2676070B1 (fr) * 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2678636A1 (fr) * 1991-07-02 1993-01-08 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes et cellules hote utilisees.
DK0524681T3 (da) 1991-07-12 2000-04-10 Dsm Nv Fremgangsmåde til oprensning af serumalbumin
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
FR2679920A1 (fr) * 1991-08-02 1993-02-05 Rhone Poulenc Rorer Sa Levures recombinantes hautement stables pour la production de proteines recombinantes, leur preparation et leur utilisation.
FR2686620B1 (fr) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2693463B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2693464B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2693475B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'identification et/ou de clonage de promoteurs transcriptionnels, et utilisation de ces promoteurs pour l'expression de gènes.
FR2694294B1 (fr) * 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisateur.
DE4226971C2 (de) * 1992-08-14 1997-01-16 Widmar Prof Dr Tanner Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
CA2136564C (en) * 1993-11-26 2008-04-08 Kaoru Kobayashi Process for producing human serum albumin
EP0699687B1 (de) * 1994-08-31 2004-01-28 Mitsubishi Pharma Corporation Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
EP1586329A1 (de) † 2000-02-08 2005-10-19 Allergan, Inc. Pharmazeutische Zusammensetzungen mit botulinum Toxin
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2305312B1 (de) 2001-10-10 2015-03-04 ratiopharm GmbH Neumodulierung und Glykokonjugation von Follitropin (FSH)
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
KR100441384B1 (ko) * 2002-01-08 2004-07-21 주식회사 안지오랩 인간 혈청 알부민-팀프-2 융합 단백질 발현시스템 및재조합 인간 혈청 알부민-팀프-2 융합 단백질
KR20110014661A (ko) 2002-02-07 2011-02-11 노보자임스 바이오파마 디케이 에이/에스 알부민-융합 쿠니츠 도메인 펩타이드
US7517671B2 (en) 2002-02-28 2009-04-14 New England Biolabs, Inc. Methods and compositions for concentrating secreted recombinant protein
CN101172091B (zh) 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
EP1615945B1 (de) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
GB0329681D0 (en) * 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
EP1729795B1 (de) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albuminfusionsproteine
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
EP2054437A2 (de) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
EP2201036A1 (de) 2007-08-08 2010-06-30 Novozymes Biopharma DK A/S Transferrinvarianten und konjugate
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
CA2729322C (en) 2008-06-24 2020-05-26 Technische Universitaet Muenchen Muteins of hngal and related proteins with affinity for a given target
CA2749786A1 (en) 2009-01-16 2010-07-22 Jason Benjamin Bock New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
BR112012002709A2 (pt) 2009-08-05 2019-04-30 Pieris Ag formulações de liberação controlada de muteínas de lipocalina
EP3660510A3 (de) 2009-12-07 2020-07-08 Pieris Pharmaceuticals GmbH Muteine von humanem lipocalin 2 (lcn2, hngal) mit affinität für ein bestimmtes zielmolekül
CA2784861A1 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
US8986951B2 (en) 2010-06-08 2015-03-24 Pieris Ag Tear lipocalin in muteins binding IL-4 R alpha
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Pharmaceuticals Gmbh Binding proteins for hepcidin
EP2640740B1 (de) 2010-11-15 2017-03-15 Pieris Pharmaceuticals GmbH Muteine von menschlichem lipocalin 2 mit affinität für glypican-3 (gpc3)
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
ES2863410T3 (es) 2011-12-13 2021-10-11 Pieris Pharmaceuticals Gmbh Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores.
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
JP6498601B2 (ja) 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
US10126304B2 (en) 2013-01-16 2018-11-13 George Mason Research Foundation, Inc. Binding domain mapping
EP2968490A1 (de) 2013-03-14 2016-01-20 Daiichi Sankyo Co., Ltd. Neuartige bindeproteine für pcsk9
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
SG10201912019WA (en) 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
DE102014011653A1 (de) * 2014-06-20 2015-12-24 Ulrich Loos Nachweis von Autoantikörpern gegen den TSH-Rezeptor
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
AU2016212087B2 (en) 2015-01-28 2019-11-07 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
BR112017017530A2 (pt) 2015-02-18 2018-04-17 Sanofi proteínas específicas para pioverdina e pioquelina
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
RU2736312C2 (ru) 2015-05-04 2020-11-13 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Белки, специфичные в отношении cd137
AU2016262845B2 (en) 2015-05-18 2020-07-23 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
PL3298140T3 (pl) 2015-05-19 2024-11-12 Yale University Kompozycje do leczenia patologicznych stanów zwapnienia i sposoby ich stosowania
EP3115371A1 (de) 2015-07-07 2017-01-11 Sanofi Fusionsmoleküle
KR20180029238A (ko) 2015-07-15 2018-03-20 피어이스 파마슈티컬즈 게엠베하 Lag-3에 특이적인 신규 단백질
EA035586B1 (ru) 2015-11-30 2020-07-10 Пиерис Острелиа Пти Лтд. Новые антиангиогенные слитые белки
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2018134274A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for lag-3
HRP20230590T2 (hr) 2018-07-31 2024-02-16 Pieris Pharmaceuticals Gmbh Novi fuzijski protein specifičan za cd137 i pd-l1
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
JP2023527908A (ja) 2020-06-05 2023-06-30 ピエリス ファーマシューティカルズ ゲーエムベーハー ４－１ｂｂをターゲティングする多量体免疫調節物質
EP4320141A1 (de) 2021-04-08 2024-02-14 Pieris Pharmaceuticals GmbH Neue für den bindegewebewachstumsfaktor (ctgf) spezifische lipocalinmuteine
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
TW202428603A (zh) 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079739A3 (de) * 1981-11-12 1984-08-08 The Upjohn Company Auf Albumin basierende Nukleotiden, ihre Replikation und Verwendung und Plasmide zur Verwendung darin
IE55817B1 (en) 1982-05-19 1991-01-30 Gist Brocades Nv Cloning system for kluyveromyces species
FR2532656B2 (fr) 1982-06-02 1985-10-18 Elf Bio Rech Nouveau vecteur de clonage et d'expression, levure et bacterie transformees par ce vecteur
FR2579223B1 (fr) 1985-03-25 1988-12-09 Genetica Procede de preparation microbiologique de la serum-albumine humaine
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
JPS62215393A (ja) 1986-01-13 1987-09-22 ジエネツクス・コ−ポレ−シヨン バチルス中でのヒト血清アルブミンの製造
FR2594846B1 (fr) 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
IT1203758B (it) * 1986-03-27 1989-02-23 Univ Roma Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
GB8620926D0 (en) * 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
ES2061632T5 (es) * 1987-07-28 2000-12-16 Dsm Nv Kluyveromyces como celula hospedante.
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
IL89992A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
CA2017176A1 (en) * 1989-05-22 1990-11-22 Yoshitomi Pharmaceutical Industries Ltd. Albumin gene-containing plasmid, transformant carrying same, production of such transformant and production of albumin

Also Published As

Publication number Publication date
DK383189D0 (da) 1989-08-04
JP3068139B2 (ja) 2000-07-24
NO893149L (no) 1990-02-06
DK383189A (da) 1990-02-06
HUT51329A (en) 1990-04-28
AU3933289A (en) 1990-02-08
NO893149D0 (no) 1989-08-03
EP0361991A3 (de) 1992-10-14
DE68929115T2 (de) 2000-06-15
PT91381A (pt) 1990-03-08
JPH02276589A (ja) 1990-11-13
EP0361991B1 (de) 1999-12-15
FI893702L (fi) 1990-02-06
FR2649991A2 (fr) 1991-01-25
ATE187775T1 (de) 2000-01-15
AU623425B2 (en) 1992-05-14
EP0361991A2 (de) 1990-04-04
FR2649991B2 (fr) 1994-03-04
NZ230229A (en) 1991-07-26
DK175846B1 (da) 2005-03-29
KR910004800A (ko) 1991-03-29
FI893702A7 (fi) 1990-02-06
FI893702A0 (fi) 1989-08-04
PT91381B (pt) 1995-05-31

Similar Documents

Publication Publication Date Title
DE68929115D1 (de) Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe
DE68928380D1 (de) Expression von menschlichen Serumalbumin in methylotrophischen Hefen
AU6733487A (en) Mammalian interleukin-4
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
EP0341746A3 (de) Expression von Hepatitis B S und preS2 Proteinen in methylotrophen Hefen
ATE125298T1 (de) Verfahren zur herstellung von motilinähnlichen polypeptiden und seine expression.
DE3882154D1 (de) Verfahren zur herstellung des pres 1/s2/s-hepatitis-b-antigens aus hefe.
DE68925044D1 (de) Herstellung von Fusionsproteinen oder -polypeptiden
ATE132160T1 (de) Verfahren zur reinigung von aussenmembran-protein von haemophilus influenza
DE59005082D1 (de) Antikörper gegen hochkonservierte Aminosäuresequenzen von immunogenen Substanzen, Verfahren zur Herstellung dieser Antikörper, sowie deren Verwendung in Immunoassays.
ATE92962T1 (de) Mikrobiologisches verfahren zur gewinnung eines proteins durch zuechtung eines mutanten bakterienstammes.
FI934079L (fi) Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY, FR